keyboard_arrow_up

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

ResearchMoz.us include new market research report" Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech " to its huge collection of research reports.

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

 

View Full This Report With TOC @ http://www.researchmoz.us/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


List of Figures:

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

Figure 2: Agreements signed by phase of development (2007-2013), % of all deals

Figure 3: Components of the pure licensing deal structure

Figure 4: Payment options for discovery, preclinical and clinical stage partnering deals

Figure 5: Issues affecting royalty rates

Figure 6: Discovery stage partnering frequency 2007-2013

Figure 7: Big pharma – top 50 – discovery stage deals 2007 to 2013

Figure 8: Big pharma discovery stage deal frequency – 2007 to 2013

Figure 9: Big biotech – top 50 – discovery stage deals 2007 to 2013

Figure 10: Big biotech discovery stage deal frequency – 2007 to 2013

Figure 11: Discovery stage partnering by deal type since 2007

Figure 12: Discovery stage partnering by disease type since 2007

Figure 13: Discovery stage partnering by technology type since 2007

Figure 14: Preclinical stage partnering frequency 2007-2013

Figure 15: Big pharma – top 50 – preclinical stage deals 2007 to 2013

Browse All Latest Report Related to Pharmaceutical @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

For More Information Kindly Contact: 


Tel:+1-518-618-1030 

Toll Free: 866-997-4948

Email  :sales@researchmoz.us

Website:http://www.researchmoz.us/

Blog   :http://globalmarketresearchnews.blogspot.com/